A Worldwide Health Crisis That Needs Us All
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A liver condition characterized by inflammation and damage due to excessive fat. It is often associated with metabolic risk factors such as obesity, type 2 diabetes, and metabolic syndrome.
The disease marks a progression from simple steatosis, where fat accumulates in the liver without causing damage, to metabolic associated steatohepatitis (MASH), a more severe form involving inflammation and liver cell damage.
Metabolic Dysfunction-Associated Steatohepatits (MASH)
MASH denotes a critical stage of liver disease, encompassing severe fibrosis, cirrhosis, or even liver cancer. This stage requires immediate medical intervention.
The progression from a healthy liver to MASLD and potentially MASH involves several stages, starting with
- fat accumulation (steatosis)
- advancing to inflammation (steatohepatitis)
- possibly leading to severe liver damage including fibrosis, cirrhosis, and liver cancer.
Early stages are often asymptomatic, with later stages leading to symptoms such as fatigue, abdominal pain, and jaundice.
Common Statistics
-
Approximately 25% - 30 % of the world's population is affected by MASLD, with a subset developing MASH.
-
Obesity and type 2 diabetes are significant risk factors, increasing the likelihood of progressing to MASH.
-
Liver diseases, including MASLD and MASH, are among the leading causes of liver transplants worldwide.
Living with MASLD & MASH
Managing MASLD and MASH involves dietary changes, increased physical activity, and regular medical monitoring. Mental health support is also crucial, as chronic illnesses can significantly impact psychological well-being.
These Patient Advocacy and Education organizations provide resources for patients, support advocacy efforts, and offer educational materials on liver health.